Claims for Patent: 9,308,284

Summary for Patent: 9,308,284

Title:	Formulations of fluorinated stilbene suitable for PET imaging
Abstract:	The invention is directed to formulations of lipophilic Amyloid beta ligand stilbene and more particularly to formulations which are capable to be administered parenterally e.g. intravenously, wherein the lipophilic Amyloid beta ligand stilbene is a fluorinated stilbene. Further, the invention is directed to a method for sterile filtration of formulations suitable for PET imaging of mammals pursuant to the invention.
Inventor(s):	Carsten Olbrich, Michael Krause, Andreas Burkhard, Annett RICHTER, Rainer Braun
Assignee:	Life Molecular Imaging Ltd
Application Number:	US14/128,015
Patent Claims:	1. A pharmaceutical formulation comprising: 0.03 GBq/mL to 5 GBq/mL of Compound 2 of the following formula having an 18F fluoro radioisotope group: 8% v/v to 25% v/v of ethanol, 10% w/v to 25% w/v of poly(ethylene glycol), 0.01% to 3% w/v of ascorbic acid, and 0.01% to 20% w/v of sodium ascorbate. 2. The pharmaceutical formulation according to claim 1 comprising: 0.03 GBq/mL to 5 GBq/mL of Compound 2, 15% v/v of ethanol, 20% w/v of PEG 400 poly(ethylene glycol), 0.44% w/v of ascorbic acid, and 2.88% w/v of sodium ascorbate. 3. A pharmaceutical formulation comprising: 0.01 μg/mL to 5 μg/mL of Compound 2 of the following formula having an 18F fluoro radioisotope group: 8% v/v to 25% v/v of ethanol, 10% w/v to 25% w/v of poly(ethylene glycol), 0.01% to 3% w/v of ascorbic acid, and 0.01% to 20% w/v of sodium ascorbate. 4. The pharmaceutical formulation according to claim 3 comprising: 3 μg/mL of Compound 2, 15% v/v of ethanol, 20% w/v of PEG 400, 0.44% w/v of ascorbic acid, and 2.88% w/v of sodium ascorbate.